Metabolomic Profiling of Mice Serum during Toxoplasmosis Progression Using Liquid Chromatography-Mass Spectrometry

Chun-Xue Zhou¹,²,* Dong-Hui Zhou¹,* Hany M. Elsheikha³, Yu Zhao¹, Xun Suo² & Xing-Quan Zhu¹

Better understanding of the molecular changes associated with disease is essential for identifying new routes to improved therapeutics and diagnostic tests. The aim of this study was to investigate the dynamic changes in the metabolic profile of mouse sera during *T. gondii* infection. We carried out untargeted metabolomic analysis of sera collected from female BALB/c mice experimentally infected with the *T. gondii* Pru strain (Genotype II). Serum samples were collected at 7, 14 and 21 day post infection (DPI) from infected and control mice and were subjected to liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-Q-TOF-MS)-based global metabolomics analysis. Multivariate statistical analysis identified 79 differentially expressed metabolites in ESI+ mode and 74 in ESI− mode in sera of *T. gondii*-infected mice compared to the control mice. Further principal component analysis (PCA) and partial least squares-discrimination analysis (PLS-DA) identified 19 dysregulated metabolites (5 in ESI+ mode and 14 in ESI− mode) related to the metabolism of amino acids and energy metabolism. The potential utility of these metabolites as diagnostic biomarkers was validated through receiver operating characteristic (ROC) curve analysis. These findings provide putative metabolite biomarkers for future study and allow for hypothesis generation about the pathophysiology of toxoplasmosis.

*Toxoplasma gondii* is an obligate intracellular protozoan pathogen that can infect any warm-blooded animal species and virtually any nucleated cell types, which makes *T. gondii* a highly prevalent parasitic infection with up to one third of the world's human population has been estimated to be infected¹. While infection in immunocompetent people is asymptomatic, *T. gondii* can cause retinochoroiditis and encephalitis in immunocompromised individuals, and has been a frequent cause of abortion or congenital toxoplasmosis in pregnant women². Variation in the clinical manifestations and severity of the disease is determined by both the host's genetic background and the genotype of the infecting parasite strain³. Type I strains are lethal (LD100~1), and in contrast, type II and III strains are significantly less virulent (LD100 ≥ 10³)⁴. In North America and Europe, Type II strains are responsible for human toxoplasmosis and chronic infections in food animals⁵.

The prognosis of toxoplasmosis largely depends on the stage of *T. gondii* infection. Acute infection is caused by the tachyzoite stage of the parasite, and as infection progresses tachyzoite transforms to the bradyzoite form, which is associated with long-term chronic infection, where the parasite persists for many years or the life-time of the host⁶. *T. gondii* strictly relies on host cellular metabolism to obtain the energy and biosynthetic building blocks required for their replication⁷. But, very little is known about the physiological state and biochemical

---

¹State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province 730046, PR China. ²National Animal Protozoa Laboratory and College of Veterinary Medicine, China Agricultural University, Beijing 100193, PR China. ³Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonnington Campus, Loughborough, LE12 5RD, UK. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to X.S. (email: suoxun@cau.edu.cn) or X.Q.Z. (email: xingquanzhu1@hotmail.com)
landscapes of both the host and parasite during these acute and chronic infections. During chronic infection, *T. gondii* enters a quiescent state; however there is a possibility that even the latent parasite stage exerts a considerable impact on the host metabolic profiles. The alteration in the metabolism of the host during acute and latent stages of *T. gondii* infection needs to be defined in order to better understand the pathogenesis of toxoplasmosis (e.g., the potential role of quiescence in combating host parasitidal responses) and develop drugs that target processes essential for parasite survival during latency.

How an intracellular pathogen such as *T. gondii* manipulates the metabolism of its host in order to create a more hospitable metabolic niche has been a central question in toxoplasmosis research. *T. gondii* is in a constant competition with its host over access to carbon sources and nutrients because this parasite needs to tailor its metabolism to fulfill particular tasks, such as the synthesis of virulence factors or the maintenance of its energy/redox state in hospitable host environments. Recently, a pioneering study has investigated the metabolic needs and capabilities of *T. gondii* using a combined computational and experimental approach. The interplay between *T. gondii* parasites and their hosts has been studied for decades using targeted approaches, such as the analysis of mutants or host immunological responses. Although much has been learned from such studies, they focus on individual pathways and fail to reveal the global effects of infection on the host's metabolism. To address this limitation, high-throughput methods, such as transcriptomics and proteomics, have been used to study host-*T. gondii* interactions. However, the effect of *T. gondii* on the biochemical composition of host body fluids remains unknown. *T. gondii*, although strictly intracellular, has been detected in body fluids. These extracellular niches may provide different nutrient availability or other benefits and challenges. Therefore, a complete understanding of *T. gondii* pathogenesis necessitates consideration of the effect of the parasite on the metabolism of body fluids over time. In this regard, host serum offers an important window for understanding the biological changes that occur in host during infection.

Recently, techniques that detect and quantify multiple small chemical metabolites in complex biological samples have been developed, giving rise to the field of metabolomics. Metabolomic studies have relied on the use of analytical platforms, such as nuclear magnetic resonance (NMR), gas or liquid chromatography coupled to mass spectrometry (GC-MS/LC-MS) and capillary electrophoresis/mass spectrometry (CE-MS) for the analysis of the metabolome. Among these techniques, LC/MS has been widely used in metabolites' identification and quantification, and has been a useful metabolomic method with high sensitivity, peak resolution, and reproducibility. Also, it can identify and quantify hundreds of metabolites with higher mass accuracy, thus allowing comprehensive metabolic profiling. This non-targeted metabolomic approach enables changes in many metabolites to be evaluated in an unbiased fashion, and thus can provide a global view of dynamic metabolic variations, simulating the changes that occur during the disease development, which can allow the discovery of key metabolites that are able to discriminate healthy individuals from patients.

We used LC-Q/TOF-MS metabolomic-based approach to investigate the impact of *T. gondii* infection on host metabolism using BALB/c as a model. To our knowledge, this is the first comprehensive metabolomic analysis of the effect of *T. gondii* infection on host serum metabolism. Our findings indicate that LC-MS-based untargeted metabolomic analysis is able to identify deregulated metabolites in mouse serum and discriminate the metabolomic profile between *T. gondii*-infected and non-infected mice, as well as during the different stages of the disease. A few mammalian signaling pathways of fundamental importance for host metabolic and immune homeostasis have been affected, including pathways involved in host amino acid, lipid and energy signaling. The disruption of such pathways reveals the significant impact of *T. gondii* infection on host metabolic function and may shed light on the molecular mechanisms used by *T. gondii* to cause disease, as well as those used by host defenses.

**Results**

**Characteristics of infected mice.** Control mice did not exhibit any clinical signs during the entire course of infection. However, infected mice showed time-dependent increase in the progression of illness. Infection has been assessed via the detection of *T. gondii* B1 gene in various mouse tissues and all infected mice were tested positive (data not shown). At 7 DPI mice showed mild signs, which progressed to typical clinical signs of acute infection at 10 DPI. By 14 DPI mice began to recover and at 21 DPI all mice restored their normal physical state. Using H&E staining, spleen and brain samples were examined for histopathological damages caused by *T. gondii*. As expected, all control mice tissues did not show any obvious pathological changes. In contrast, infected mice showed splenomegaly at 14 DPI (Fig. S1). Also, a reduced white pulp with an expansion of the red pulp compartment was observed at 14 DPI (Fig. 1A). Brain of infected mice had inflammatory reactions characterized by focal mononuclear cell infiltrates and glial nodules at 14 and 21 DPI. A number of multifocally distributed tissue cysts filled with bradyzoites were detected at 21 DPI (Fig. 1C).

**Comparative metabolite profiling of serum from infected mice and controls.** We next analyzed all total ion chromatograms of mice sera. We noted a stable retention time without peaks' drifts (Fig. S2). Representative TIC chromatograms of serum samples from infected mice are shown (Fig. 2). Baseline correction, peak deconvolution, alignment, normalization and median-centering are applied to process the data, and there are 509 and 532 retention time–exact mass pairs determined in each sample profile analyzed in positive or negative ion mode, respectively. The majority of peaks in the chromatograms are identified as endogenous metabolites and most of these metabolites are involved in multiple biochemical processes, especially in energy and lipid metabolism. The LC–MS system stability and reproducibility for the large-scale sample analysis were observed in the PCA scores plot representation of QC samples by using the metabolite profiles obtained in positive and negative ion modes, as shown in Fig. S3. Six QC samples were run for serum samples throughout the entire analysis. There was no drift in the PCA scores plot representation of QC samples, and 87.2% and 93.2% of RSDs were less...
than 30% for serum samples in the positive mode and negative mode, respectively. Therefore, the LC–MS system repeatability and stability were deemed acceptable.

To investigate the metabolic variations during the disease progression, all observations acquired in both ion modes were first analyzed using two components PCA score trajectories plot (Fig. S4). The score plot did not illustrate good classification of the infected mice groups and their corresponding control groups. Subsequently, the cross-validated two-component PLS-DA models were used for further multivariate analysis, and showed a satisfactory modeling. To reduce the system error and interference of impurity peak, the OPLS-DA model of SIMCA-P were then established for the following analysis.

Temporal variation in metabolic profiling. To better define the metabolic variations in mice serum after *Toxoplasma gondii* infection, all observations acquired in both ion modes were analyzed using OPLS-DA. Generally, the model is believed to be reliable when the $Q^2 > 0.4$. As shown in Fig. 3 the scores plots of OPLS-DA model discriminated the infected groups from their corresponding control groups, which exhibited satisfactory classification. The differential metabolites at different times post infection were selected according to the VIP threshold ($VIP > 1$) in the OPLS-DA model and the $p$-value of student’s $t$-test ($p < 0.05$) after FDR correction. As shown in Fig. 4A–C the serum metabolic states of the infected mice deviated significantly from their corresponding controls in the ESI+ mode. The serum metabolic profiling in the infected mice changed most significantly from their controls at 7 DPI. As the infection time increases the number of differential metabolites decreased, indicating a restoration of the dysregulated metabolic state in a time-dependent manner. Meanwhile, metabolic profile observed in ESI- mode also exhibited the same trend (Fig. S5). Of the 79 differential metabolites detected in ESI+ mode, 43 were shared between at least two of the three infection stages (Fig. 4D). Also, we detected 74 significant differential metabolites in ESI- mode, of which 43 were shared between at least two of three infection stages (Fig. 4E). As shown in Table 1, we detected 15 metabolites under ESI+ and 7 metabolites under ESI- that varied at all three time points. The related pathways of each metabolite were also listed by searching the KEGG pathway database (http://www.genome.jp/kegg/), and the majority of these 22 metabolites were involved in lipid metabolism and amino acid metabolism.

Figure 1. Histopathological lesions in mouse tissues infected with *Toxoplasma gondii* Pru strain (10 cysts per mouse by oral route, H&E stain). (A) A section of spleen from infected mice at 14 DPI. Pentagram indicates the largely scattered white pulp; (B) A section of spleen from normal mice at 14 DPI showing no histological abnormalities; (C) Brain histology of infected mice at 21 DPI. Arrow indicates the tissue cyst; (D) Brain histology of normal mice at 21 DPI without any pathological changes. Magnifications: 40X (A,B); 100X (C,D).
Metabolic Variations between different stages. To further our understanding of the effects of T. gondii infection on host serum metabolism, we examined the changes in the chemical composition of serum extracts during different stages of the infection as defined by histopathology. As shown in Fig. 5 score plot from supervised OPLS-DA showed good discrimination between different infected animal groups in both positive and negative ion modes, which indicated that their metabolic profiles were distinct. Those significantly changed metabolites were then used to construct heat maps for unsupervised clustering. As shown in Fig. 6, heat maps of the differential metabolites detected in ESI$^+$ mode showed a clear clustering for each group in agreement with the OPLS-DA results. Mice at 14 and 21 DPI were recovering from the acute infection, and exhibited the minimal difference in the number of differential metabolites (Fig. 6C). At 7 DPI mice would be soon developing an acute infection stage, exhibited the larger number of differential metabolites when compared with other two infected groups (Fig. 6A,B). We also constructed heat maps using differential metabolites detected in ESI$^-$ mode. Even though sample clusters overlapped slightly, most samples were clearly grouped into two differentiated clusters and subsequent statistic analysis revealed dramatic time-dependent changes in the number of differential metabolites (Fig. S6).

Identification of potential biomarkers. The potential biomarker metabolites that significantly contributed to the discrimination of infected mice from controls were identified by using the receiver operating characteristic (ROC) curve analysis in MetaboAnalyst 3.0\textsuperscript{21}. Firstly, univariate ROC curve analyses were applied to quantify the predictive performance of each potential biomarker. The sensitivity and specificity trade-offs were calculated for each selected metabolite using the area under the ROC curve (AUC). This analysis identified 5 significantly differential metabolites in ESI$^+$ mode and 14 significantly differential metabolites in ESI$^-$ mode with AUC > 0.8, which were selected after standardization of data as shown in Table 2. 3D PCA models and heat maps were constructed using the marker metabolite intensities as variables. As shown in Fig. 7 and Fig. S7, the infected mice group and the control group were separated into two different regions.

To evaluate the utility of metabolite combination for the diagnosis of T.gondii infection, multivariate exploratory ROC analysis was performed. ROC curves are generated by Monte-Carlo cross validation (MCCV) using balanced subsampling. Different biomarker modules were created through the built-in feature selections. As shown in Fig. 8, the AUC values obtained in this analysis were 0.996 (95% C.I. 0.951-1) and 1 (95% C.I. 1-1) for all the 5 marker metabolites in ESI$^+$ mode and 14 marker metabolites in ESI$^-$ mode, respectively (an ideal model would have an AUC of 1). Together, these results indicate that the identified potential biomarkers, alone or in...
combination, can discriminate the infected samples from the controls with high accuracy and could be powerful indicators for Toxoplasmosis monitoring.

Discussion

Host-pathogen interactions have been studied using several "omics" techniques, such as genomics, transcriptomics, and proteomics, and more recently metabolomics, a newly established omics’ methodology based on the analysis of small metabolites to study chemical changes in biological properties22. The use of these omics methodologies has revealed important information about many biological systems and has greatly contributed to the development of systems biology. In the present study we performed a LC-Q/TOF-MS-based untargeted metabolomic study to investigate the global effect of T. gondii infection on the serum metabolism of BALB/c mice. Our results show that T. gondii infection causes significant dynamic changes in the metabolite balance of the serum of T. gondii-infected mice and identified novel biomarkers with potential diagnostic value.
Fifteen metabolites detected in ESI+ mode and 7 metabolites in ESI- mode were found to vary during the 21 day of the infection period (Table 1). They represent perturbations in multiple pathways, such as pyrimidine metabolism, lipid metabolism and tryptophan metabolism\(^23\). Among these metabolites, kynurenine, phosphatidylethanolamine (PE) (18:0)/phosphatidylcholine (PC) (15:0) were increased, whereas, the level of choline, glycerophosphocholine, serotonin, cytidine, N-Acetyl-DL-tryptophan, arachidonic acid and eicosatrienoic acid were decreased. These infection-specific metabolic alterations are consistent with the current understanding of host-\(T. gondii\) interaction biology. Metabolic function is known to influence the activity of the immune system\(^24\). In this regard, \(T. gondii\) infection induces major immunological changes, that in some cases are linked to the production of amino acid metabolites, such as kynurenine (consistent with our finding), a product of indoleamine 2,3 dioxygenase (IDO) enzymatic degradation of tryptophan; a key antiparasitic mechanism to control parasite growth\(^25\). The induction of IDO by interferon-\(\gamma\) (IFN-\(\gamma\)) and some pro-inflammatory cytokines is associated
with depleted plasma tryptophan (in agreement with our finding), which may interfere with brain 5-HT synthesis, and increased production of anxiogenic and depressogenic tryptophan catabolites. Evidence showed that kynurenine might be involved in depression and cognitive deficits, which explains the depressive and anxiety symptoms exhibited by the infected mice. Serotonin is another metabolite in tryptophan metabolism and its depletion is also associated with depression, and anxiety. The exact mechanism of this behavioral manipulation is unknown, but parasites cysts to disturb dopamine metabolism has been suggested as one of the most appealing causes. A previous study showed that infection of mice by *T. gondii* caused a 14% increase in whole-brain dopamine levels upon establishment of chronic infection. In agreement with this finding our study showed a time-dependent differential expression of DA may explain the link between abnormal behavioral alterations and *T. gondii* infection.

A clear metabolites’ separation has been observed not only between infected mice and the corresponding controls, but also between different infected mouse groups throughout the course of the infection (Fig. 6). The alterations in the serum metabolic profile of *T. gondii*-infected mice paralleled the clinical course of the disease, where the significant changes in metabolites were detected in infected mice at 7 DPI, followed by restoration of the metabolic profile to a normal level as infection proceeds to the chronic stage, indicating a re-balance of the disturbed metabolic state coinciding with regaining apparently normal physical status.

Previous applications of LC-MS based unbiased metabolomic technologies has enabled researchers to identify biomarkers for various diseases, such as cancer and other types of disease, and to investigate host-parasite interaction and metabolic alterations in trypanosomiasis, schistosomiasis and malaria in a high-throughput manner. In agreement with previous studies, our results demonstrated the power of the untargeted LC-MS-based metabolomics’ approach in profiling the metabolic changes in serum from *T. gondii*-infected mice. We identified 19 infection-specific metabolites, 5 in ESI+ mode and 14 in ESI- mode, in the serum samples. PCA models and heat maps constructed based on those selected metabolites showed reasonable separations between infected and control groups. ROC analysis supported the robustness of the PCA models by cross validation, in which all ROC value were high. Among these compounds, the 5 detected in ESI+ mode, including kynurenine, serotonin, glycero-phosphocholine and choline and N-Acetyl-DL-tryptophan, showed higher sensitivity and specificity (Fig. 8).

### Table 1. List of dysregulated metabolites identified in the serum of mice throughout the entire infection process.

| Metabolites | ESI+ | ESI- |
|---|---|---|
| **Choline** | 104.1072 | 14.19 |
| **Glycerophosphocholine** | 258.1101 | 0.95 |
| **Valine** | 118.0863 | 0.65 |
| **Methionine** | 150.0584 | 0.35 |
| **L-Tyrosine** | 182.0812 | 1.18 |
| **Phenylpyruvic acid** | 165.0544 | 1.25 |
| **Serotonin** | 177.1022 | 1.39 |
| **Phosphorylcholine** | 170.0598 | 1.16 |
| **Spermidine** | 146.0601 | 1.31 |
| **Tryptophan** | 205.0972 | 1.16 |
| **Trans-Hexadec-2-enoyl carnitine** | 398.3268 | 1.46 |
| **PE(18:0)/PC (15:0)** | 482.3424 | 0.36 |
| **PE (O-16:0)/PC (O-13:0)** | 440.3137 | 0.66 |
| **PE(20:3)** | 504.3066 | 1.14 |
| **Cytidine** | 242.0798 | 0.81 |
| **L-Leucine** | 130.0873 | 0.51 |
| **N-Acetyl-DL-tryptophan** | 245.0933 | 2.25 |
| **1-hexadecanoyl-sn-glycero-3-phosphocholine** | 508.3408 | 0.21 |
| **Arachidonic Acid** | 303.2328 | 0.65 |
| **Eicosatrienoic acid** | 305.2488 | 0.60 |

**Metabolic pathways:**
- Glycine, serine and threonine metabolism; Glycerophospholipid metabolism; bile secretion
- Glycerophospholipid metabolism
- Valine, leucine and isoleucine degradation and biosynthesis
- Cysteine and methionine metabolism
- Tyrosine metabolism; Phenylalanine metabolism; Phenylalanine, tyrosine and tryptophan biosynthesis; Thiamine metabolism
- Phenylalanine metabolism; Phenylalanine, tyrosine and tryptophan biosynthesis
- Tryptophan metabolism; bile secretion
- Not known
- Pyrimidine metabolism
- Not known
- Tyrosine metabolism
- Valine, leucine and isoleucine degradation; Valine, leucine and isoleucine biosynthesis
- Not known
- Not known
- Valine, leucine and isoleucine degradation
- Not known
- Not known
- Not known
- Not known
- Not known
Methods

Ethics statement. All animal procedures were approved by Animal Ethics Committee of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences ( Permit No. LVRIAEC2014-002). All experiments were performed in strict compliance with the requirements of the Animal Ethics Procedures and Guidelines of the People’s Republic of China.

Mice. Female BALB/c mice were purchased from Lanzhou University, China. All mice were bred and maintained under specific-pathogen-free (SPF) conditions in the experimental facility at Lanzhou University, where they received sterilized food and water ad libitum. All mice were kept in a temperature-controlled room (22 ± 0.5 °C) on reverse 12/12 h light/dark cycle. Mice were acclimated for about seven days prior to the start of the experiment and were weighed (weight > 20 g) to establish a baseline for detecting any reduction in body weight caused by infection.

Figure 5. OPLS-DA score plot showing a clear separation between the infected serum samples at different time points after infection. (A) The 7D infected group vs the 14D infected group (R²X = 0.782, R²Y = 1, Q² = 0.953 ESI+; R²X = 0.717, R²Y = 1, Q² = 0.946 ESI−); (B) The 21D infected group vs the 7D infected group (R²X = 0.433, R²Y = 0.997, Q² = 0.952 ESI+; R²X = 0.517, R²Y = 0.996, Q² = 0.954 ESI−); (C) The 21D infected group vs the 14D infected group (R²X = 0.604, R²Y = 0.988, Q² = 0.93 ESI+; R²X = 0.539, R²Y = 0.957, Q² = 0.808 ESI−). (a) ESI+, (b) ESI−. X axis is PC1, Y axis is PC2.
Parasite strain, its maintenance, and mouse infection. *Toxoplasma gondii* type II Prugnuaud (Pru) strain was maintained in mice via oral inoculation of cysts in mice. Cysts used in this study were isolated from brain tissues of infected BALB/c mice 40 days post-infection (DPI). Following anesthetizing animals, the brains of infected mice were removed and homogenized under sterile conditions. Then, the number of cysts was counted and diluted to 100 cysts/ml in phosphate buffered saline solution (PBS, pH 7.2). Mice (6–8 weeks old) were infected with freshly prepared 10 cysts of *T. gondii* Pru strain by oral gavage. Mock-infected (control) mice underwent the identical infection protocol but with plain PBS without any parasite cysts. All mice were monitored for mortality and morbidity throughout the course of infection (i.e. 21 DPI).

Table 2. Potential marker metabolites detected in LC/MS chromatograms.

| Ion mode | Metabolites                        | Rt (min) | P-value      | AUC  | Log2 (FC) | Metabolic pathways                  |
|----------|------------------------------------|----------|--------------|------|-----------|-------------------------------------|
| ESI (−)  | Oleic acid                         | 14.51    | 1.14E-03     | 0.827| −0.67     | Fatty acid biosynthesis             |
| ESI (−)  | Eicosapentaenoic Acid              | 14.29    | 1.31E-05     | 0.843| −0.88     | Biosynthesis of unsaturated fatty acids |
| ESI (−)  | Arachidonic Acid                  | 13.69    | 9.90E-06     | 0.889| −0.83     | Arachidonic acid metabolism         |
| ESI (−)  | HOME                               | 13.58    | 5.84E-06     | 0.886| −0.85     | Not known                           |
| ESI (−)  | PC (15:0)                          | 12.45    | 6.75E-05     | 0.898| 0.52      | Not known                           |
| ESI (+)  | Glycrophospho-N-Palmitoyl Ethanolamine | 11.22  | 2.70E-03     | 0.836| 0.27      | Not known                           |
| ESI (−)  | PE (16:0)                          | 11.22    | 2.10E-04     | 0.867| 0.32      | Not known                           |
| ESI (−)  | Tauric acid                        | 8.05     | 1.01E-03     | 0.802| 1.26      | Taurine and hypotaurine metabolism; bile secretion |
| ESI (−)  | N-Acetyl-DL-tryptophan             | 5.95     | 2.71E-07     | 0.963| −1.94     | Not known                           |
| ESI (−)  | L-Phenylalanine                    | 2.34     | 1.29E-04     | 0.843| 0.33      | Aromatic amino acid metabolism      |
| ESI (+)  | Kynurenine                         | 2.27     | 1.54E-04     | 0.997| 1.77      | Tryptophan metabolism               |
| ESI (+)  | Serotonin                          | 1.79     | 3.52E-10     | 0.975| −1.69     | Tryptophan metabolism               |
| ESI (−)  | Fumaric acid                       | 1.36     | 1.12E-03     | 0.923| −0.77     | TCA cycle                           |
| ESI (+)  | Citric acid                        | 1.21     | 5.01E-05     | 0.855| −0.62     | TCA cycle                           |
| ESI (−)  | Glutathione, oxidized              | 1.21     | 1.22E-03     | 0.824| −0.87     | Glutathione metabolism; Methane metabolism |
| ESI (−)  | Malic acid                         | 1.17     | 1.10E-02     | 0.883| −0.69     | Not known                           |
| ESI (+)  | Glycerophosphocholine              | 0.81     | 8.48E-09     | 0.978| −1.37     | Glycerophospholipid metabolism      |
| ESI (−)  | Cytidine                           | 0.81     | 4.01E-05     | 0.882| −0.73     | Pyrimidine metabolism               |
| ESI (+)  | Choline                            | 0.78     | 6.00E-07     | 0.938| −0.93     | Glycerophospholipid metabolism      |

Figure 6. Heat map showing the significantly dysregulated metabolites identified between different infected groups in ESI+ mode. Individual samples are separated using hierarchical clustering, with the dendrogram scaled to represent the distance between each branch. Heat maps show a clear separation of the metabolomic profile between different infected groups. Normalized signal intensities (log2 transformed and row adjustment) are visualized as a color spectrum and the scale from least abundant to highest ranges is from −2.0 to 2.0. Green color indicates low expression, and red color indicates high expression of the detected metabolites. (A) 7D infected group vs 21D infected group; (B) 7D infected group vs 14D infected group; (C) 14D infected group vs 21D infected group.
Confirmation of infection. Following anesthetizing animals, 6 mice from infected or control groups were sacrificed at 7, 14 and 21 DPI. Mice tissues, such as brain, blood, liver, spleen, lung, small intestine and kidney were collected and examined for the presence of *T. gondii*. Briefly, genomic DNA was extracted from these tissues using TIANamp Genomic DNA kit (TianGen™, Beijing, China) according to the manufacturer’s instructions. Then, a PCR targeting the *T. gondii* B1 gene was performed to detect infection using the specific primers (5′-AAC GGG CGA GTA GCA CCT GAG GAG-3′ and 5′-TGG GTC TAC GTC GAT GGC ATG ACA AC-3′)40. Positive control (DNA from parasites) and negative control (PBS) samples were included in each test. Infection was also confirmed by histopathological examination of brain and spleen collected from the mice after euthanasia. Tissue samples were fixed in 10% neutral buffered formalin solution for 2 weeks and then were dehydrated by gradually soaking in alcohol and xylene and embedded in paraffin. The paraffin-embedded specimens were cut into 5-μm sections, stained with hematoxylin-eosin (H&E), and examined under a digital optical microscope (Olympus, Tokyo, Japan).

Non-targeted metabolic profiling and spectral acquisition. The blood samples from different infection groups (7d, n = 6; 14d, n = 6; 21d, n = 6) and their corresponding control groups (n = 6) were prepared as described previously41. Blood was collected by retro-orbital bleed into Eppendorf tubes directly and allowed to clot for 30 min followed by centrifugation at 3000 g for 10 minutes at 4°C to collect the serum fraction.
Supernatants were frozen immediately at −80 °C and shipped on dry ice. A total of 100 μl serum sample was thawed on ice at 4 °C and then precipitated by a solvent of acetonitrile-water (7:3), treated with ultrasonic wave for 15 min. The mixture was centrifuged at 12,000 rpm for 15 min at 4 °C and then the supernatant was transferred to 1.5 ml polypropylene tube.

Metabolomic analysis was performed using an Agilent 1290 Infinity LC System coupled to an Agilent 6530 Q-TOF/MS (Agilent Corp.) (LC-Q/TOF-MS) equipped with an electrospray ionization (ESI) source. The separation of all samples was performed on a C18 column (Agilent Technologies, Santa, Clara, CA) (dimension 100 × 2.1 mm, 1.8 μm particle size, 100 Å pore size) with the column temperature maintained at 40 °C. The LC-MS system was run in a binary gradient solvent mode consisting of 0.1% (v/v) formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) and the flow rate was 0.4 ml/min. The linear gradient is described in Table 3.

The sample injection volume was 4 μl. Sample analysis was carried out in both positive and negative ion modes. The mass scanning range was 50−1000 m/z. Nitrogen was used as the dry gas and cone gas with parameters described in Table 4. The mass spectrometry was operated in V optics mode and the data acquisition rate was set to 0.03 s, with interscan delay of 0.02 s. To ensure accuracy and reproducibility, LockSpray was used in all analyses and Leucine-enkephalin was selected as the lockmass for positive ([MH]+ = 556.2771) and negative ([MH]− = 554.2615) ion modes.

We used Quality control (QC) samples to assess the reproducibility and reliability of the LC-MS system. QC samples were prepared by mixing equal volumes (10 μl) from each serum sample as they were aliquoted for analysis. This “pooled” sample was used to provide a “mean” profile representing all the analytes encountered during the analysis. The pooled “QC” sample was injected five times at the beginning of the run to ensure system equilibrium and then every 6 samples to further monitor the stability of the analysis.

Data processing and statistics. Raw data were acquired by using LC-MS-Q-TOF MassHunter Workstation QTOF Acquisition software (B.03.01) (Agilent Technologies, Santa Clara, CA, USA) in an untargeted mode. LC-MS raw data file was converted into common format, and then directly processed by the XCMS toolbox (http://metlin.scripps.edu/xcms/) [44]. Peak picking, peak grouping and retention time correction were all involved in data pre-treatment, which was done through the XCMS software that was implemented with the freely available R programming language (v 2.13.1). Retention time (RT)-m/z data pairs were used to identify ion intensities of those detected peaks. The consistent variables (ion intensity information) were obtained by filtering peaks with 80% missing values and those with isotope ions from each group.

In order to remove the offsets and adjust the importance of high and low abundance metabolites to an equal level, the data was pre-processed by both mean-centering and variance-scaling prior to multivariate analysis. Then, the resulting three-dimensional matrix, which includes assigned peak indices (retention time-m/z pairs), sample names and variables, was further subjected to multivariate data analysis.

The resulting scaled datasets were imported into SIMCA-P + 11.0 (Umetrics, Umea, Sweden) where multivariate analyses such as principal components analysis (PCA) and orthogonal partial least-squares-discriminant analysis (OPLS-DA) were carried out to investigate and visualize the pattern of metabolite changes in an un-supervised and supervised manner, respectively. PCA was used to validate quality of the analytical system performance and to observe possible outliers. OPLS-DA was applied to obtain an overview of the complete dataset and discriminate the variables that are responsible for variation between the groups. The quality of the models was evaluated with the relevant R2 and Q2 as well discussed elsewhere. The differential metabolites were selected when the statistically significant threshold of variable influence on projection (VIP) values obtained from the

| Time(min) | Flow rate (mL/min) | A (%) | B (%) |
|-----------|-------------------|-------|-------|
| 0         | 0.4               | 95    | 5     |
| 2         | 0.4               | 95    | 5     |
| 17        | 0.4               | 5     | 95    |
| 19        | 0.4               | 5     | 95    |

Table 3. The gradient of mobile phase.

|                | Positive ion mode | Negative ion mode |
|----------------|-------------------|-------------------|
| Capillary voltage | 4 kV              | 3.4 kV            |
| Sampling cone   | 35 kV              | 50 kV             |
| Source temperature | 100 °C           | 100 °C            |
| Desolvation temperature | 350 °C        | 300 °C            |
| Cone gas flow   | 50 L/h             | 50 L/h            |
| Desolvation gas flow | 600 L/h         | 700 L/h           |
| Extraction cone | 4 V                | 4 V               |

Table 4. Mass spectrometry parameters.
OPLS-DA model was larger than 1.0. Meanwhile, the p values from a two-tailed Student's t-test on the normalized peak areas were less than 0.05. Log 2 fold change (FC) was used to show how these selected differential metabolites varied between groups. The dataset of selected differential metabolites was imported into MetaboAnalyst 3.0 for heatmap generation and multivariate statistics. The areas (AUC) under the receiver operating characteristic curves (ROC) were constructed to evaluate the effectiveness of potential biomarkers. Results were considered significant when p value is less than 0.05.

Putative metabolites were first derived by searching the exact molecular mass data from redundant m/z peaks against the online HMDB (http://www.hmdb.ca/), METLIN (http://metlin.scripps.edu/) and KEGG (www.genome.jp/kegg/) databases. A specific metabolite was sieved out when a match with a difference between peaks against the online HMDB, METLIN and KEGG value is less than 0.05.

Significance when tic curves (ROC) were constructed to evaluate the effectiveness of potential biomarkers. Results were considered 3.0 for heatmap generation and multivariate statistics. The areas (AUC) under the receiver operating characteristic curves (ROC) were constructed to evaluate the effectiveness of potential biomarkers. Results were considered significant when p value is less than 0.05.

References

1. Weiss, I. M. & Dubey, J. P. Toxoplasmosis: A history of clinical observations. Int. J. Parasitol. 39, 895–901 (2009).
2. Jones, J. L., Kruszon-Moran, D., Sanders-Lewis, K. & Wilson, M. Toxoplasma gondii infection in the United States, 1999–2004, decline from the prior decade. Am. J. Trop. Med. Hyg. 77, 405–410 (2007).
3. Grigg, M. E., Ganatra, J., Boothroyd, J. C. & Margolis, T. P. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J. Infect. Dis. 184, 633–639 (2001).
4. Dubey, J. History of the discovery of the life cycle of Toxoplasma gondii. Int. J. Parasitol. 39, 877–882 (2009).
5. Howe, D. K. & Sibley, L. D. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J. Infect. Dis. 172, 1561–1566 (1995).
6. Yarovinsky, E. Innate immunity to Toxoplasma gondii infection. Nat. Rev. Immunol. 14, 109–121 (2014).
7. Kafsaek, B. F. & Llinás, M. Eating at the table of another: metabolomics of host-parasite interactions. Cell Host Microbe 7, 90–99 (2010).
8. Zhou, C. X. et al. Global metabolomic profiling of milk brains following experimental infection with the cyst-Forming Toxoplasma gondii. PLoS One 10, e0139635 (2015).
9. Laliberta, J. & Carruthers, V. B. Host cell manipulation by the human pathogen Toxoplasma gondii. Cell. Mol. Life Sci. 65, 1900–1915 (2008).
10. Tymoshenko, S. et al. Metabolic needs and capabilities of Toxoplasma gondii through combined computational and experimental analysis. PLoS Comput. Biol. 11, e1004261 (2015).
11. Lemieux, C. S. et al. Parasite manipulation of the invariant chain (Ii/CD74) and the peptide editor H2-DM affects MHC-II antigen presentation during Toxoplasma gondii infection. Infect. Immun. 83, 3865–3880 (2015).
12. Legal, V. et al. AMA1-deficient Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity. Infect. Immun. 83, 2475–2486 (2015).
13. Nelson, M. et al. Modulation of the host cell proteome by the intracellular apicomplexan parasite Toxoplasma gondii. Infect. Immun. 76, 828–844 (2008).
14. Pinna, K. J., Aliota, M. T. & Knoll, L. J. Dual transcriptional profiling of mice and Toxoplasma gondii during acute and chronic infection. BMC Genomics 15, 806 (2014).
15. Kupferschmidt, O. et al. Quantitative detection of Toxoplasma gondii DNA in human body fluids by TaqMan polymerase chain reaction. Clin. Microbiol. Infect. 7, 120–124 (2001).
16. Arantes, T. E. et al. Toxoplasma gondii: Evidence for the transmission by semen in dogs. Exp. Parasitol. 123, 190–194 (2009).
17. Olszewski, K. L. et al. Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe 5, 191–199 (2009).
18. Zhou, B., Xiao, J. F., Tuli, L. & Ressom, H. W. LC-MS-based metabolomics. Mol. Biosyst. 8, 470–481 (2012).
19. Teodoridis, G., Gika, H. G. & Wilson, I. D. LC-MS-based methodology for global metabolite profiling in metabonomics/metabolomics. TrAC Trends. Anal. Chem. 27, 251–260 (2008).
20. Naz, S., Vallejo, M., Garcia, A. & Barbas, C. Method validation strategies involved in non-targeted metabolomics. J. Chromatogr. A 1353, 99–105 (2014).
21. Xia, J., Sinelnikov, I. V., Han, B. & Wishart, D. S. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res. 43, W251–257 (2015).
22. Zhang, W., Li, F. & Nie, L. Integrating multiple ‘omics’ analysis for microbial biology: application and methodologies. Microbiology 156, 287–301 (2010).
23. Henderson, J. F. & Paterson, A. R. P. Nucleotide metabolism: an introduction. (Academic Press, 2014).
24. Mathis, D. & Shoelster, S. E. Immunometabolism: an emerging frontier. Nat. Rev. Immunol. 11, 81–83 (2011).
25. Silva, N. M. et al. Expression of indoleamine 2, 3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. Infect. Immun. 70, 859–868 (2002).
26. Leonard, B. & Maes, M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and comitigants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 36, 764–785 (2012).
27. Dantzer, R., O’Connor, J. C., Lawson, M. A. & Kelley, K. W. Inflammation-associated depression: from serotonin to kynurenic acid. Psychoneuroendocrinology 36, 426–436 (2011).
28. Wonodi, I. & Schwarcz, R. Cortical kynurenic pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr. Bull. 36, 211–218 (2010).
29. Cai, X. et al. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat. Neurosci. 16, 464–472 (2013).
30. Frandovskiy, E. et al. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS One 6, e23866 (2011).
31. Stibbs, H. Changes in brain concentrations of catecholamines and indoleamines in Toxoplasma gondii infected mice. Ann. Trop. Med. Parasitol. 79, 153–157 (1985).
32. Fergusson, D. & Hutchison, W. An ultrastructural study of the early development and tissue cyst formation of Toxoplasma gondii in the brains of mice. Parasitol. Res. 73, 483–491 (1987).
33. Xiao, J. F. et al. LC-MS-based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J. Proteome Res. 11, 5914–5923 (2012).
34. Peng, J., Chen, Y. T., Chen, C. L. & Li, L. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-biomarker discovery. Anal. Chem. 86, 6540–6547 (2014).
35. Huybrechts, B., Martins, J., Deboningie, P., Uhlig, S. & Callebaut, A. Fast and sensitive LC-MS/MS method measuring human mycotoxin exposure using biomarkers in urine. Arch. Toxicol. 89, 1993–2003 (2014).
36. Xu, D. D. et al. Discovery and identification of serum potential biomarkers for pulmonary tuberculosis using iTRAQ-coupled two-dimensional LC-MS/MS. Proteomics 14, 322–331 (2014).
37. Li, J. V. et al. Metabonomic investigation of single and multiple strain Trypanosoma brucei brucei infections. Am. J. Trop. Med. Hyg. 84, 91–98 (2011).
38. Balog, C. I. et al. Metabonomic investigation of human Schistosoma mansoni infection. Mol. Biostat. 7, 1473–1480 (2011).
39. Lakshmanan, V. et al. Metabolomic analysis of patient plasma yields evidence of plant-like α-linolenic acid metabolism in Plasmodium falciparum. J. Infect. Dis. 206, 238–248 (2012).
40. Hill, D. E., Chirukandoth, S., Dubey, J., Lunney, J. K. & Gamble, H. Comparison of detection methods for Toxoplasma gondii in naturally and experimentally infected swine. Vet. Parasitol. 141, 9–17 (2006).
41. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA. 106, 3698–3703 (2009).
42. Zelena, E. et al. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal. Chem. 81, 1357–1364 (2009).
43. Luan, H. et al. Pregnancy-induced metabolic phenotype variations in maternal plasma. J. Proteome Res. 13, 1527–1536 (2014).
44. Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779–787 (2006).
45. Guo, L. et al. Three plasma metabolite signatures for diagnosing high altitude pulmonary edema. Sci. Rep. 5, 15126; doi: 10.1038/srep15126 (2015).
46. Wiklund, S. et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal. Chem. 80, 115–122 (2008).
47. Xu, Y. et al. Evaluation of accurate mass and relative isotopic abundance measurements in the LTQ-orbitrap mass spectrometer for further metabolomics database building. Anal. Chem. 82, 5490–5501 (2010).

Acknowledgements
Project support was provided by the National Natural Science Foundation of China (Grant No. 31230073) to X.Q.Z. We thank BGI-Shenzhen for technical assistance.

Author Contributions
X.Q.Z. and X.S. designed the research. C.X.Z., D.H.Z. and Y.Z. performed the research. D.H.Z. and H.M.E. contributed reagents/materials/analyses. C.X.Z. analyzed the data. C.X.Z., H.M.E. and X.Q.Z. wrote the paper.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhou, C.-X. et al. Metabolomic Profiling of Mice Serum during Toxoplasmosis Progression Using Liquid Chromatography-Mass Spectrometry. Sci. Rep. 6, 19557; doi: 10.1038/srep19557 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/